Liquid formulation of pentoxifylline is a poorly tolerated treatment for Duchenne dystrophy

OBJECTIVE: To perform an open label, pilot study of an orally administered liquid formulation of immediate release pentoxifylline (PTX) to patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety and tolerability were assessed. METHODS: The tolerability and safety of PTX, measures...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Zimmerman, A., Clemens, P.R., Tesi-Rocha, C., Connolly, A., Iannaccone, S.T., Kuntz, N., Arrieta, A., Hache, L., Henricson, E., Hu, F., Mayhew, J., Escolar, D.M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3136640/
https://ncbi.nlm.nih.gov/pubmed/21674534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mus.22127
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы